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Abstract 
Myasthenia Gravis (MG) is an autoimmune disease triggered by antibodies directed against proteins 
involved in cell signaling at the neuromuscular junctions, resulting in failure of the neuromuscular 
transmission and muscle weakness (Conti-Fine et al., 2006). The majority of these autoantibodies (≈85%) 
are directed to the nicotinic acetylcholine receptor (anti-AchR antibodies) present in skeletal muscle 
cells, but the exact area of the receptor that is targeted is still not known (Tzartos et al., 1991).  There is 
however a significant group of patients that do not express these antibodies. This heterogeneity may 
be associated with different characteristics regarding the specific target, the affinity or avidity of the 
antibodies and it may account for different clinical phenotypes. Furthermore, due to the non-
specificity of the drugs currently available, some patients respond poorly or not respond at all to 
treatment. Recently,  patients with MG have been treated with Rituximab, a drug that targets CD20 
positive cells, (a membrane associated phosphoprotein present in the surface of every B-cell, except 
stem cells, pro-B-cells and effector B-cells), and resulting in the complete depletion of circulating B-
cells. However, not all patients with MG respond to this therapy. 
This study aimed at determining what is the specific molecular target that is bound by the pathogenic 
antibodies and whether these antibodies are produced by CD20-positive B cells. We started by 
investigating a specific region of 10-amino acid sequence (WNPDDYGGVK) corresponding to the 
residues 67-76 of the extracellular domain of alpha1 subunit of AchR that has been suggested to be 
involved as a potential target, in an animal model of MG. Simultaneously the extracellular domain of 
the alpha1 subunit of acetylcholine receptor (CHRNA1) was synthesized by molecular cloning, to allow 
the subsequent isolation of different peptides and determination of their potential role as targets.  
Serum samples from patients with MG were collected and tested for IgG antibodies that recognized 
this specific region of 10-amino acid sequence and CHRNA1 cloned protein, by enzyme-like 
immunosorbent assay (ELISA). Furthermore we intended to identify whether patients had CD20+ B 
lymphocytes involved in the production of these pathogenic antibodies, using flow cytometry. All 
patients gave informed consent before entering the study. 
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We showed that the serum from seropositive patients for the AchR did not recognize 
the WNPDDYGGVK synthetic peptide, which suggests that the MIR peptide described to be the main 
immunogenic region in antibody targeting in animal models of the disease (EAMG), might not be the 
same in humans. However, patients with MG seropositive for the AchR had antibodies directed 
towards the CHRNA1 suggesting that this subunit might be the main targeted region in this disease. 
The detection of CD20+ B lymphocytes involved in the production of these pathogenic antibodies can 
provide an easy tool to identify patients that might respond to anti-CD20 drugs, such as rituximab. 
Keywords: Autoantibodies; Antibodies anti-AchR; Myasthenia Gravis. 
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Resumo 
A Miastenia Gravis é uma doença auto-imune caracterizada pela presença de autoanticorpos que 
reconhecem proteínas envolvidas na sinalização neuromuscular, desencadeando falhas na 
transmissão neuromuscular e fraqueza muscular (Conti-Fine et al., 2006). Maioritariamente estes 
anticorpos (≈85%) apresentam uma elevada afinidade para o receptor nicotínico de acetilcolina 
(anticorpos anti-AchR) presente nas células musculares esqueléticas (Tzartos et al., 1991). Devido à falta 
de especificidade dos fármacos disponíveis actualmente, alguns doentes respondem de forma 
incompleta, ou não respondem de todo, ao tratamento. Recentemente, alguns doentes com MG 
iniciaram tratamento com Rituximab, um fármaco que tem como alvo o CD20, uma fosfoproteína 
associada à membrana celular presente na superfície de todas as células B (excepto as células 
estaminais, células pró-B e as células B de memória), o que resulta na depleção das células B 
circulantes. No entanto, nem todos os doentes respondem de forma significativa a este tratamento.  
Este estudo teve como objectivo investigar quais poderiam ser as potenciais regiões antigénicas no 
receptor nicotínico de acetilcolina (AchR). Começámos por investigar uma região específica de 10 
aminoácidos (WNPDDYGGVK) que corresponde aos resíduos 67-76 do domínio extracelular da 
subunidade alfa 1 do AchR. Simultaneamente, o domínio extracelular da subunidade alfa 1 do 
receptor de acetilcolina (CHRNA1) foi sintetizado por clonagem.  
Todos os doentes assinaram um consentimento informado antes de entrar no estudo. Amostras de 
soro de doentes com MG foram usadas para testar a existência de anticorpos IgG que possam 
reconhecer a sequência específica de 10 aminoácidos e também a proteína CHRNA1 clonada, por 
ensaio imuno-enzimático (ELISA). Além disso pretendeu-se identificar, por citometria de fluxo, se os 
linfócitos B envolvidos na produção destes anticorpos patogénicos são CD20+. 
O desenvolvimento de um método de ELISA específico mostrou que os doentes com anticorpos anti-
AchR não apresentavam títulos de anticorpos que reconhecessem o péptido sintético WNPDDYGGVK, 
o que sugere que o péptido MIR descrito como a principal região imunogénica para os anticorpos em 
modelos animais da doença (EAMG), pode não ser o mesmo em seres humanos. Os resultados obtidos 
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pressupõem a existência de outras regiões antigénicas no AchR nicotínico. Na sequência da 
identificação dos alvos específicos correctos, a detecção de linfócitos B CD20+ envolvidos na produção 
destes anticorpos patogénicos pode proporcionar uma ferramenta fácil de identificar doentes que 
possam responder a fármacos anti-CD20, como o Rituximab. 
Palavras-chave: Autoanticorpos; Anticorpos anti-AchR; Miastenia Gravis. 
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1.1. Myasthenia Gravis 
Myasthenia Gravis (MG) is an autoimmune disease triggered by antibodies directed against proteins 
involved in signalling at the neuromuscular junction (NMJ), resulting in failure of the neuromuscular 
transmission, muscle weakness and abnormal fatigability. It is characterized by gradual impairment of 
daily activities such as sitting up, brush the teeth, rise from a chair, talk, chew, swallow and even 
breath. The patients’ weakness fluctuates every day and tends to get worse with activity and 
ameliorates with rest (Kaminski, 2009; Meriggioli et al., 2009).  
In Europe the incidence ranges from 3 to 30 per million and the prevalence is between 15 and 179 per 
million inhabitants. The increasing prevalence registered in the past decade is mostly due to improved 
diagnostic techniques and treatments that increase longevity. This disease occurs in both genders but 
the incidence is higher in women (Andersen et al., 2014).  
1.1.1. Forms of Myasthenia Gravis 
Myasthenia Gravis can be classified based on the location of affected muscles, antibody profile and 
age of onset (Berrih-Aknin et al., 2014; Kaminski, 2009).  
a) Location of affected muscles 
The ocular form of MG is diagnosed when symptoms are limited to the ocular muscles for at least two 
years. The most common symptoms are ptosis, which is the abnormal lowering or drooping of the 
upper eyelid caused by muscle weakness or paralysis, and/or diplopia, a visual defect in which a single 
object is seen in duplicate (Meriggioli et al., 2009). 
In approximately 15% of patients with MG the symptoms remain limited to the extrinsic ocular 
muscles, with a greater prevalence in men over the age of 40. However, symptoms may progress to 
the bulbar muscles (muscles of the mouth and throat responsible for speech and swallowing) and limb 
muscles, resulting in a generalized form of MG (Berrih-Aknin et al., 2014; Conti-Fine et al., 2006). In these cases the 
symptoms include dysphagia, dyspnea, dysarthria (difficulty in articulating words caused by 
impairment of the muscles used in speech) and facial weakness.  
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When respiratory muscle weakness is acute and severe (myasthenic crisis), tracheal  intubation may 
be necessary for ventilator support or airway protection. 
b)  Antibody profile 
Most of the autoantibodies in patients with Myasthenia Gravis are directed to the nicotinic 
acetylcholine receptor (≈85%) and are called anti-AchR antibodies (Conti-Fine et al., 2006; Jayam Trouth et al., 
2012; Meriggioli et al., 2009; Rodgaard et al., 1987; Sine, 2012; Vincent et al., 1982; Vincent et al., 1980). However other proteins 
present in the neuromuscular junctions, such as Muscle-Specific Kinase (MuSK) (Conti-Fine et al., 2006; Evoli et 
al., 2008; Illa et al., 2008; Meriggioli et al., 2009; Zisimopoulou et al., 2013), titin (Yamamoto et al., 2001) and rapsyn (Agius et al., 
1998) may also be targeted, resulting in myasthenic symptoms.  
Like AchR, MuSK is a postsynaptic transmembrane protein present in muscle cells at the NMJ, and is 
involved in neuromuscular transmission. In mature neuromuscular synapses, the MuSK protein is part 
of the agrin receptor (agrin is a protein produced by motor neurons and secreted into the synaptic 
basal lamina). 
In clinical practice, the antibody profile of patients with Myasthenia Gravis is performed using a 
commercial kit in which AchR is used as antigen (kit Acetylcholine Receptor Autoantibodies (ARAb) 
RRA KIPIB21021 – DIAsource ImmunoAssays). Patients who present autoantibodies against the AchR 
(>0,4nmol/L according to the kit’s instructions) are designated seropositive, whilst the remaining 
patients are classified as seronegative patients. 
c)  Age of  onset 
Myasthenia Gravis with an onset before the age of 50 is classified as early-onset (EO-MG). Most of 
these patients have elevated titters of autoantibodies against the acetylcholine receptor. It is reported 
that there is a female predominance (60-70%) (Berrih-Aknin et al., 2013).  
The late-onset form of Myasthenia Gravis (LO-MG) designates the form of disease present in patients 
whose onset of symptoms occurred between the ages of 50 and 60 years. These patients have 
autoantibodies that recognize striated muscle proteins other than the AchR and MuSK (double 
seronegative patients). It is clinically important to distinguish the early-onset MG from the late-onset 
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MG. This last group is more prone to develop thymoma and is frequently associated with the 
generalized form of MG with severe respiratory crises. 
The very late-onset MG (VLO-MG) is considered when symptoms appear after 60 years of age and 
there is a male predominance in this form of MG. 
1.2. Anti-AchR antibodies in Myasthenia Gravis 
Myasthenia Gravis is an organ-specific autoimmune disease mediated by antibodies binding to the 
post-synaptic acetylcholine receptors. These antibodies found in patients with MG are polyclonal and 
heterogeneous in their action, as they may interact with distinct areas of the acetylcholine receptors 
(Meriggioli et al., 2009; Vincent et al., 1982; Vincent et al., 1980; Zisimopoulou et al., 2013). The identification of  which classes 
and subclasses of antibodies are involved in the immune response against the AchR and subsequent 
myasthenic symptoms may be important, since it determines the underlying pathologic mechanism, 
(e.g. complement activation and cell cytotoxicity depends on the presence of specific antibodies) 
(Rodgaard et al., 1987).  
Several studies have shown that, in Myasthenia Gravis, anti-AchR antibodies belong to the IgG class 
with a predominance of the IgG1 and IgG3 subtypes (Meriggioli et al., 2009; Rodgaard et al., 1987; Vincent et al., 1982; 
Vincent et al., 1980), whilst antibodies against MuSK are mainly IgG4. Several groups have measured these 
antibodies by different techniques, such as solid-phase radioimmunoassay (RIA) (Shinomiya et al., 1981; 
Tzartos et al., 1988), ELISA (Papadouli et al., 1993), indirect ELISA (Wang et al., 2010), immunoprecipitation (Hara et al., 
1993; Lefvert et al., 1978; Meriggioli et al., 2009) and flow cytometry (Allman et al., 2011) amongst others, (Meriggioli et al., 
2009) obtaining similar results. 
The serum concentration of anti-AchR IgG antibodies is highly variable amongst patients with the 
same degree of disease and may be similar between patients with different grades of muscle 
weakness and so it cannot be directly correlated or predict the severity of the disease. However, if the 
disease remains stable, the antibody titres have a tendency not to change. Therefore, in an individual 
patient the antibody concentration in the serum varies with the disease severity: upon treatment the 
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antibody titres decrease and with increasing severity the concentration of the antibodies rises (Allman et 
al., 2011; Kaminski et al., 2012; Lefvert et al., 1978; Meriggioli et al., 2009; Rodgaard et al., 1987). 
Nevertheless, the correlation between antibody titres and disease severity is not statistically 
significant, suggesting that the total burden of antibodies present might mask the titres of the specific 
antibody that is being pathogenic (Willcox et al., 1984), i.e., the antibodies measured may not be the ones 
directly implicated in the disease. Therefore it is necessary to identify the antibodies that recognize 
specific immunogenic areas on the receptor or subtypes that might be more pathogenic, and measure 
them instead of the total amount of antibodies (IgG) (Rodgaard et al., 1987). Rodgaard et al quantified the 
concentration of IgG1 and IgG3 antibodies from patients with MG, finding that both immunoglobulins 
tend to increase with disease severity, but only the IgG1 subtype can eventually be related with 
disease progression. Further studies are necessary to confirm if in fact IgG1 antibodies can be 
correlated with the progression of Myasthenia Gravis and if they can be used as biomarkers for the 
severity of the disease. 
1.2.1. Consequences of the anti-AchR antibody binding to acetylcholine receptor 
The binding of an antibody to the acetylcholine receptor can cause disruption of the neuromuscular 
junction, with loss of functional AchRs and consequent failure of the neuromuscular transmission by 
three different pathogenic mechanisms (Conti-Fine et al., 2006; Meriggioli et al., 2009; Tuzun et al., 2013) (Figure 1): 
a) Complement activation at the neuromuscular junction – results from the morphological 
deformation of the post-synaptic membrane and loss of AchR that consequently leads to the 
impairment of the neuromuscular transmission. This mechanism also induces a decrease of 
the voltage-gated Na+ channels, enhancing the action potential threshold of the muscle 
membrane. Due to specific characteristics of IgG1 and IgG3 immunoglobulins the lysis of the 
muscle endplate caused by complement activation is consistent with the idea that these 
subtypes of antibodies are found in patients with MG and might be associated with the onset 
and progression of the disease. 
 6 
b) Antigenic modulation – some antibodies against the AchR are capable of linking two molecules 
hence inducing an accelerated internalization and subsequent degradation of those cross-
linked receptors (a process designated as antigenic modulation). The fast endocytosis of the 
acetylcholine receptors needs to be balanced with an increased synthesis, otherwise there will 
be a significant loss of AchR availability at the neuromuscular junction leading to muscle 
weakness and consequently, to the symptoms present in MG. Antigenic modulation is not 
triggered by all anti-AchR antibodies as the antibodies’ capacity to cross-link two molecules is 
dependent on the localization of the epitope in the receptor. 
c) Functional AchR block – in this unusual mechanism the antibodies have affinity to the 
acetylcholine binding site on the receptor, blocking the access of acetylcholine to that site. 
Consequently, neuromuscular transmission is interrupted and muscle activation does not 
occur. Even a low concentration of these anti-AchR antibodies, may be enough to block the 
access of acetylcholine to the receptor. 
 
Figure 1 – Consequences of anti-AchR antibody binding to AchR 
A) Complement activation at the NMJ with the consequent morphological deformation of the post-synaptic membrane and 
loss of AchR. B) Antigenic modulation: antibodies against AchR are capable of linking two molecules inducing accelerated 
internalization and subsequent degradation of those cross-linked receptors. C) Functional AchR block mechanism in which 
antibodies have affinity to the acetylcholine binding site on the receptor blocking the access of acetylcholine to that site and 
interrupting neuromuscular transmission.  
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In Myasthenia Gravis it is possible to have the three pathogenic mechanisms occurring simultaneously, 
at the same neuromuscular junction, which lowers the efficiency of many therapeutic approaches. 
1.3. Treatment of Myasthenia Gravis 
The therapeutic approach of MG is based on non-antigen specific immunotherapies. These therapies 
can be classified into conventional, which includes corticosteroids and immunosuppressive drugs such 
as azathioprine, mycophenolate mofetil and cyclosporine, or immunomodulating therapies like 
intravenous immunoglobulin (IVIg) or plasmapheresis. Conventional drugs have demonstrated to be 
advantageous in the chronic treatment of Myasthenia Gravis, however these drugs are non-specific 
and their efficiency and tolerance is different between patients. Furthermore, the last group provides 
only a short-term effect instead of a continuous immunosuppression and therefore is only useful for 
myasthenic crisis (Collongues et al., 2012; Dalakas, 2012; Dalakas, 2013; Dalakas, 2006; Gold et al., 2003; Kaminski, 2009; Meriggioli et 
al., 2008; Wylam et al., 2003). 
1.3.1. New therapeutic drug development for Myasthenia Gravis 
Despite the progress and quality improvement of the conventional and immunomodulating therapies 
there are still some patients that do not respond so well to the available treatments. Considering this, 
there is an urgent need to explore and develop new drugs in order to treat MG patients with higher 
specificity and efficiency, long-term effect and with less severe and extensive side effects.  
Currently there are several ongoing investigations that attempt to develop new therapeutic drugs for 
Myasthenia Gravis (Coles et al., 1999; Dalakas, 2008; Dalakas, 2012; Dalakas, 2013; Gold et al., 2003; Weinblatt et al., 1999; Wylam et 
al., 2003): 
 Monoclonal antibodies (mAbs) consist of a protein constituted by a human or humanized IgG 
molecule, or in which the hypervariable regions may be from murine origin (chimeric 
antibody). Some of the monoclonal antibodies available today are used in the treatment of 
autoimmune diseases like Multiple Sclerosis.  
 Therapeutic fusion proteins are proteins formed by an Fc region of an IgG molecule combined 
with the extracellular domain of another molecule (e.g. a receptor). These proteins can bind 
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to antibodies that recognize the molecule and subsequently induce their degradation. 
Approved fusion proteins are currently used in several diseases: Wet Macular Degeneration, 
Cryopyrin-Associated Periodic Syndromes (CAPS) and Rheumatoid Arthritis. 
There are several drugs that target B-cells in a specific way, (either monoclonal antibodies or fusion 
proteins), currently being tested in clinical trials. Two of these (Rituximab and Ofatumumab) have 
been approved by the FDA and are currently used to treat patients with Myasthenia Gravis and 
Rheumatoid Arthritis amongst other diseases. Both drugs target the CD20 molecule, a membrane-
associated phosphoprotein present in the surface of most B-cell, with the exception of stem cells, pro-
B-cells and effector B-cells, resulting in the depletion of the circulating B-cells. While Rituximab is 
directed to a specific region of the CD20 large loop, Ofatumumab recognizes different epitopes: both 
large and small loops of CD20, which leads to a more effective B-cell lysis (Coles et al., 1999; Dalakas, 2008; 
Dalakas, 2012; Dalakas, 2013). 
Although drug development is essential, it is still important to considerer that these new approaches 
are very expensive and have long-term safety issues and therefore, the overall balance risk/benefit 
needs to be taken into account before approving any new therapeutic drug. In Myasthenia Gravis, 
drug development and the identification of reliable biomarkers are still in the very beginning. 
1.4. Acetylcholine receptor 
The nicotinic acetylcholine receptor (AchR) is a ligand-gated ion-channel (ionotropic receptor) that 
mediates the communication between cells (intercellular) in non-neuronal tissues such as bronchial 
and vascular epithelia and skin, and is extremely important in the signal transmission in autonomic 
ganglia, in neuromuscular junctions – synapses between motor neurons and skeletal muscle cells – 
and in the central nervous system, acting both in presynaptic and postsynaptic membranes. 
These receptors are formed by five out of 17 known subunits: 10 alpha (α1-α10) subunits, 4 beta 
subunits (β1-β4), one gamma (γ), one delta (δ) and one epsilon (ε). In contrast to what happens in 
neuronal subtypes of the receptor, there are only two subtypes of muscle AchR that allow the 
contraction of muscle cells (Lodish et al., 2000; Quintas et al., 2008) (Figure 2-A).  
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Considering the clinical characteristics of Myasthenia Gravis, we focussed our attention in the AchRs 
present exclusively in the NMJ. Each striated muscle nicotinic AchR is formed by two α1, and three 
non-alpha: β1, δ and one γ or ε subunits, resulting in a pentameric transmembrane protein with one of 
the following compositions (α1)2β1δγ or (α1)2β1δε and a molecular weight of ≈290 kDa (Albuquerque et al., 
2009; Conti-Fine et al., 2006; Lodish et al., 2000; Psaridi-Linardaki et al., 2002; Quintas et al., 2008) (Figure 2-B). Acetylcholine 
receptors with the stoichiometry of (α1)2β1δγ are mostly found in embryonic stages whilst receptors 
with the ε subunit ((α1)2β1δε) are found in mature neuromuscular synapses. During the formation of 
the muscle endplate, the transcription of α1, β1, δ and γ subunits occurs, to form the final receptor 
((α1)2β1δγ). The AchR activation and the increasing of cell depolarization, caused by the interaction 
with its agonists, triggers the transcription of the ε subunit, i.e., the contact of the AchR with 
acetylcholine up-regulates the expression of the ε subunit. At this point occurs the transcription of 
both γ and ε subunits which will compete to form the final receptor ((α1)2β1δγ or (α1)2β1δε). 
Receptors with the subunit composition (α1)2β1δε are more stable and have less tendency to be 
degraded. Additionally these receptors provide a faster response to the ligand activation than the 
(α1)2β1δγ. Still, there are some muscles that maintain a predominant expression of the γ subunit on 
acetylcholine receptors such as the extrinsic ocular muscles (Albuquerque et al., 2009; Wanamaker et al., 2003). 
The five subunits exhibit a considerable homology in both sequence and structure. All the AchR 
subunits have a major extracellular domain, with a conserved area of approximately 200 amino acids 
(aa) in the amino-terminal, which includes a signal peptide of 20 aa, four transmembrane domains 
(with about 20 amino acids each), and a cytoplasmic loop of variable length and amino acid sequence 
between the third and fourth transmembrane domains (Figure 2-C). The first three transmembrane 
domains are extremely conserved and the fourth transmembrane domain has a 10-amino acid 
extracellular carboxyl-terminal sequence. In the major extracellular domain, all five subunits possess a 
cysteine-loop (Cys-loop) consisting of two cysteine residues separated by thirteen highly conserved 
amino acids, linked together by a disulphide bond (Albuquerque et al., 2009; Ching et al., 2011; Lodish et al., 2000; 
Quintas et al., 2008). The receptor’s subunits are designated α and non-α based on the presence or absence 
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of a cysteine pair (Cys-Cys pair) close to the entry to the first transmembrane domain (residues 192 
and 193 of the extracellular domain), which is necessary for the binding of the neurotransmitters 
(Figure 2-C).  
The acetylcholine binds to the receptor at the interface between an alpha subunit and a non-alpha 
subunit in the extracellular domain of the AchR, i.e. binds at the interface of the αδ and αγ (or αε) 
subunits (Figure 2-B)(Albuquerque et al., 2009; Cooper et al., 2004; Lodish et al., 2000).  The attachment of two 
acetylcholine molecules to their binding sites on the ionotropic receptor leads to the conformational 
changes that open the ion-channel allowing Na+ and K+ ions to pass across the membrane modifying 
its potential and resulting in the contraction of the muscle cell. When the acetylcholine binds to the 
receptor, it causes a rotational force making the second transmembrane domain of each subunit (that 
form the central pore of the ion-channel) to rotate around a vertical line central to the channel. This 
results in the replacement of the hydrophobic residues that face the central pore by more hydrophilic 
residues allowing the ions to flow across the channel (Figure 2-D) (Albuquerque et al., 2009; Conti-Fine et al., 2006; 
Cooper et al., 2004; Lodish et al., 2000; Quintas et al., 2008). 
 
   
Figure 2 - Structure of acetylcholine receptor.  
A) Structure of a NMJ with the AchR and MuSK proteins; B) AchR observed from the extracellular space with the identification 
of each subunit that constitutes the receptor and the two acetylcholine binding sites at the interfaces between the α and γ 
(or ε) subunits and the α and δ subunits; C) Schematic view of the structure common to all AchR subunits: amino-terminal 
with the conserved 200 amino acids, major extracellular domain with the Cys-loop, four transmembrane domains and 
cytoplasmic domain between the third and fourth transmembrane domains. It is also represented the Cys-pair found 
A 
B 
C 
D 
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exclusively on alpha subunits of AchR, crucial for neurotransmitters binding; D) Conformational changes caused by the 
attachment of two acetylcholine molecules to their binding sites on the ionotropic AchR: rotational forces oblige the second 
transmembrane domain of each subunit to rotate relative to the vertical central line of the channel, leading to the 
replacement of the hydrophobic residues that face the central pore by more hydrophilic residues allowing the ions to flow 
across the channel.  
1.4.1. Alpha1 subunit of the acetylcholine receptor 
In the AchR, the alpha1 subunit is the one implicated in the acetylcholine binding and is the subunit 
most biologically active. This is why we have focussed our attention in this subunit. 
The human alpha1 subunit of the AchR is codified by the CHRNA1 gene located on the chromosome 2 
(2q31.1) and initially it was thought that it was divided into eight introns and nine exons (termed P1 to 
P9), however an additional 75bp coding sequence (corresponding to another exon) located between 
exons P3 and P4 was described: the exon P3A. So this gene has two isoforms generated through 
alternate splicing of the primary RNA transcript, that can originate mRNAs with (P3A+ isoform) or 
without (P3A- isoform) the 25-amino acid sequence of the exon P3A. Both isoforms are present in the 
human skeletal muscle, nevertheless the P3A+ isoform is not expressed in some animals such as 
mouse, calf and monkey (Beeson et al., 1990; Morris et al., 1991; Saini et al., 2005), which are some of the 
experimental models used for Myasthenia Gravis (EAMG).  
The isoform that contains the P3A exon results in a 482-amino acid long protein (Figure 3) that 
includes the acetylcholine binding site and the MIR peptide (see Main immunogenic region) and has a 
molecular weight of approximately 54kDa (Psaridi-Linardaki et al., 2002). This will be the object of interest of 
this project. 
 
Figure 3 – Amino acid sequence of the P3A+ isoform of the alpha1 subunit of acetylcholine receptor 
In grey is represented the sequence corresponding to the extracellular domain of the alpha1 subunit; underlined are 
represented the four transmembrane domains and in blue is the cytoplasmic domain of the protein. 
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1.4.2. Main immunogenic region 
In MG, most autoantibodies directed to the acetylcholine receptor bind to the extracellular domain of 
the receptor. It was described (Papadouli et al., 1993; Protti et al., 1990; Tzartos et al., 1991; Tzartos et al., 1988; Tzartos et al., 
1992) in animal models of this disease, that there is a small area of the alpha1 subunit, designated main 
immunogenic region (MIR), distinct from the acetylcholine binding site, that appears to be the main 
target for antibody binding (Papadouli et al., 1993; Protti et al., 1990; Tzartos et al., 1991; Tzartos et al., 1988; Tzartos et al., 1992). 
The confirmation of the MIR localization and structure as well as the anti-AchR antibodies involved are 
essential to design new strategies for the diagnosis and treatment of Myasthenia Gravis. 
1.4.2.1.  Localization and structure of the main immunogenic region in AchR 
Previous studies demonstrated that the MIR is restricted to a 10-amino acid sequence (residues 67-76 
of the alpha1 subunit). In them, small peptides equivalent to the alpha1 subunit of AchR, with a length 
of 14 to 20 residues overlapping each other by 4 to 6 residues, were synthesized, and the attachment 
of a vast panel of anti-AchR monoclonal antibodies to those peptides was evaluated (Papadouli et al., 1993; 
Tzartos et al., 1991; Tzartos et al., 1988). 
Tzartos et al (Tzartos et al., 1988) measured the binding of fifteen monoclonal antibodies. The majority 
(eleven monoclonal antibodies) bound strongly to the peptide YNLKWNPDDYGGVKKIHI (of which six 
bound exclusively to that peptide, two also bound significantly to IEGIKYIAETMKSDQESN – because 
these monoclonal antibodies recognized the sequences Gly-Ile-Lys-Xaa-Ile or Gly-Val-Lys-Xaa-Ile that 
are present in both peptides, and three antibodies bound weakly  to other peptides). Four monoclonal 
antibodies did not recognize any peptide, however one must bear in mind that antibody binding might 
also be dependent on the peptide conformation. Taking into account these findings, these authors 
created six new peptides that matched distinct regions of the peptide that proved to be the one with 
more monoclonal antibodies binding to: YNLKWNPDDYGGVKKIHI. This study showed that every 
monoclonal antibody investigated in this experiment (eight anti-MIR antibodies) linked exclusively to 
the peptide WNPDDYGGVKWNPDDYGGVK, that includes the decapeptide WNPDDYGGVK which 
corresponds to the residues 67-76 of the alpha1 subunit (YNLKWNPDDYGGVKKIHI) (Tzartos et al., 1991; 
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Tzartos et al., 1988), suggesting that this peptide has immunodominant properties in the Experimental 
Autoimmune Myasthenia Gravis (EAMG) model and is the main site of antibody binding in the 
acetylcholine receptor. 
Years later, Papadouli et al (Papadouli et al., 1993) examined the importance of each amino acid residue in 
the MIR decapeptide by doing several amino acid substitutions with analogous amino acids, and 
subsequently analysing the binding of monoclonal antibodies to those peptides. They conclude that:  
→ The binding of the tested mAbs appears not to be dependent on the Trp67 residue;  
→ The residues Asn68, Pro69and Asp71 are essential to the MIR antigenic proprieties, as the 
substitutions of these amino acids reduce the ability of the mAbs to bind to the peptide;  
→ Antibody binding is slightly affected due to substitutions on Tyr72: in a few situations there is 
an enhancement of the antibody binding to the peptide; 
It should be considered that a single amino acid substitution in the MIR peptide can lead to a 
significant conformational change that may impair the antibody binding and therefore, the results 
obtained in this study should be considered with caution.  
Taking into account that in some residue substitutions there was an intensification of the antibody 
binding, this group suggested that a new method for the treatment of MG could involve the presence 
of a synthetic MIR peptide with greater affinity to anti-AchR antibodies, which would prevent the 
binding of the antibodies to the AchR at the NMJ (Papadouli et al., 1993).  
All the studies mentioned above reached their conclusions by using mAbs isolated from mice 
immunized with the naïve acetylcholine receptor from different species or subunits of AchR purified 
from Torpedo Californica (a specie of electric ray from the Torpedinidae family known as Pacific 
electric ray). This is a wealthy source of muscle-type AchR used as starting material for receptor 
purification, since the electric organ of these rays contains approximately 40% of this protein 
(Albuquerque et al., 2009; Kaminski et al., 2012). This can be misleading and can compromise the transition from 
animal studies to human studies for several reasons: first the immune responses developed by mice 
differ from the human ones as the characteristics of the antibodies are different between species. 
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Secondly, the affinity of the antibodies to isolated subunits of the AchR or the MIR synthetic peptides 
may be distinct from its affinity to the naïve acetylcholine receptor. Additionally, immune responses 
induced against an outside peptide do not have the same features as autoimmune responses. These 
issues are crucial when it comes to the validation of the experimental results, since they can lead to 
the use of antibodies that do not disclose the same type of response or the same binding site on the 
isolated acetylcholine receptor as those developed by patients with MG.  
One possible way to avoid these problems is identifying the B lymphocytes responsible for the 
production of the antibodies against the peptide of interest (residues 67-76 of alpha1 subunit). Allman 
et al (Allman et al., 2011) characterized B lymphocytes from peripheral blood of immunized mouse models 
with AchR purified from Torpedo Californica to induce an experimental autoimmune model of 
Myasthenia Gravis (EAMG). Then, AchRs also purified from Torpedo Californica were conjugated with 
Alexa fluor647 (originating the complex AchR-Alexa fluor647) and used as a probe to identify B 
lymphocytes that expressed at its surface immunoglobulins with affinity to the receptor, i.e., detect 
which cells were responsible for the production of autoantibodies against the AchR in EAMG models. 
Flow cytometry revealed that in EAMG mice the AchR-Alexa fluor647 complex bound to lymphocytes 
that expressed the glycoprotein B220 at their surface.  
B220 is a major transmembranar glycoprotein present in the surface of B lymphocytes, with the 
molecular weight of 220kDa. In mice, this isoform of the CD45 family is found in initial precursors of B 
cells and is maintained till the stage of mature B-cells, even after antigen recognition, and is used as a 
B-cell marker. In humans, B220 expression cannot be used has a marker since its expression is 
correlated with the CD27 expression, which is a memory B-cell marker. Human B lymphocytes can be 
divided into three main groups: B220-/CD27- (since the B220 protein is not expressed in all B 
lymphocytes), B220+/CD27- and B220-/CD27+ (Bleesing et al., 2003; Rodig et al., 2005). Initially it was thought 
that B220 was found only in naïve B-cells and that this glycoprotein could be used has a marker for 
human naïve B-cells. CD27 is a marker for memory B-cells and it was hypothesized that the contact of 
B lymphocytes with an antigen and its activation led to a B220 downregulation and an increase in the 
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CD27 expression at the cell surface, justifying the presence of lymphocytes  B220+/CD27- (naïve B-
cells) and B220-/CD27+ (memory B-cells). However, the identification of a small B220+/CD27+ B 
lymphocyte group suggested that the transition from naïve B-cells to memory B-cells would implicate 
an in-between group that would express both proteins.  
In the same set of experiments the lymphocytes that expressed B220 (B220+ lymphocytes) were 
characterized into class and subclass, showing that both groups of mice (EAMG and control) expressed 
IgM antibodies although the titres in EAMG mice were higher. Furthermore, immunoglobulins from 
the IgG2 subclass were exclusively found in the EAMG group, suggesting that these antibodies are 
specific for MG in this model (Allman et al., 2011). It is important to notice that IgG2 antibodies found in 
mice are equivalent to the IgG1 subtype in humans and so, this finding supports previous studies 
reporting that IgG1 antibodies are present in patients with MG. 
Additionally, this group found that B lymphocytes expressing IgG2 immunoglobulins could be 
correlated with disease severity in mice: the increase of B-cell titres in the peripheral blood was 
associated with an increase in muscle weakness and more severe disease stages, and therefore the 
authors proposed that these B lymphocytes could be used as biomarkers for disease severity(Allman et al., 
2011). However monoclonal antibodies that recognize B220+cells in mice do not bind to human cells 
(Rodig et al., 2005) so this proposal might not be applicable to humans. 
Furthermore, this study may also have some bias: the paratopes that exist in mice antibodies are 
different from those in humans, the subtype of antibodies responsible for certain immunogenic 
pathways vary between species, and the markers present at the surface of B-cells differ in human and 
mice since in mice the glycoprotein B220 is used as a B-cell marker whilst in humans the presence of 
this protein depends on the expression of CD27, which in turn does not exist in mice.  
1.4.2.2. Localization and structure of the main immunogenic region in human AchR 
Studies addressing B lymphocyte characterization have not been done in humans yet and it is 
therefore very important to use human molecules to validate previous research findings. 
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The first step required for the transition from animal studies to human research is to place the 
sequence that corresponds to the MIR peptide identified in previous animal studies (Papadouli et al., 1993; 
Tzartos et al., 1991; Tzartos et al., 1988) in a human acetylcholine receptor. The use of in silico tools allowed the 
visualization of its structure and possible antigenic characteristics as well as the speculation on what 
the binding sites for the autoantibodies might be.  
As shown in Figure 4 in silico analysis showed that in the human’s AchR, the immunodominant region 
(MIR peptide) is found in a β-sheet of the extracellular domain of the alpha1 subunit between the 
residues 67-76, which corresponds to the amino acid sequence WNPDDYGGVK, as previously stated. 
 
Figure 4 - Structure of alpha1 subunit of the AchR and the MIR localization. 
A) Structure of alpha1 subunit: in pink are represented α-helices, in yellow β-sheets and turns are in blue. It is possible to see 
the large extracellular domain formed by β-sheets and the amino-terminal with the α-helix (1), four transmembrane domains 
(2) and cytoplasmic domain between the third and fourth transmembrane domains (3); B) Structure of alpha1 subunit with 
the MIR peptide localization(yellow halos) in a β-sheet of the extracellular domain from residues 67-76 (WNPDDYGGVK); C) 
Similar to B), but with a clear view of MIR peptide; C1) and  C2) Amplified views of MIR location from residues 67-76 
(WNPDDYGGVK), on the extracellular domain of the alpha1 subunit of AchR. 
 
The next step of these studies would then be to confirm if patients with MG produce autoantibodies 
that recognize the MIR peptide, as well as, identify the class and subclasses of antibodies produced by 
these patients. If so, a MIR-like peptide could be used to characterize the B lymphocytes responsible 
for the production of the pathogenic autoantibodies. 
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2.1. Overall goal and specific aims 
The main target and the antibody profile of patients with Myasthenia Gravis are not yet well-defined. 
Furthermore not all patients show clinical improvement when treated with the current therapeutic 
approaches.  
This project’s overall goal is to investigate the existence of different antigen regions in the nicotinic 
acetylcholine receptor targeted by autoantibodies produced by patients with Myasthenia Gravis, 
enabling the use of those targets and/or the corresponding anti-AchR antibodies as biomarkers for 
both diagnostic and/or treatment response in Myasthenia Gravis. 
Considering that one study performed in mice identified one peptide (MIR) present in the alpha1 
subunit of the AchR as the main target of antibody binding, it is necessary to determine if patients 
with Myasthenia Gravis produce autoantibodies against the same MIR peptide (AchR+ and MIR 
peptide+) and, if so, distinguish them from those that do not recognize the MIR peptide, but do have 
autoantibodies against other regions of the alpha subunit of the AchR (AchR+ and MIR peptide-). 
Furthermore, it would be important to identify the B lymphocyte population responsible for the 
production of the autoantibodies against the AchR, particularly whether they express CD20 as that 
could provide grounds for the use of specific drugs.  
To do so, specific aims were outlined: 
a. Develop a fusion protein of the extracellular domain of the alpha 1 subunit of the AchR. 
b. Identify whether the MIR peptide and/or other peptides obtained from the production of the 
extracellular domain of the alpha1 subunit of the AchR are targeted by human antibodies 
present in serum from patients with MG. 
c. Identify and characterize the B lymphocyte sub-population responsible for the production of 
the autoantibodies in patients with Myasthenia Gravis. 
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All assays and laboratory procedures described in this chapter were optimized and systematically 
revised in order to minimize inter and intra-assay variability. 
3.1. Patients & Healthy controls 
14 patients with Myasthenia Gravis attending Prof. Doutor Fernando Fonseca Hospital, Amadora, 
Portugal were enrolled in this study, and 14 volunteer healthy subjects sex- and age-matched were 
also included and used as controls. The current investigation was approved by the Ethics Committees 
of Prof. Doutor Fernando Fonseca Hospital and all subjects gave informed consent before entering the 
study.  
Blood samples from patients with Myasthenia Gravis and healthy subjects were collected and both 
serum and peripheral blood mononuclear cells (see procedure below) were isolated and stored at -80ºC 
until analysis.  
3.1.1. Antibody profile 
The antibody profile of the patients with Myasthenia Gravis was performed using a commercial kit in 
which the AchR was used as antigen (kit Acetylcholine Receptor Autoantibodies (ARAb) RRA 
KIPIB21021 – DIAsource ImmunoAssays). Patients whose serum presented autoantibodies against the 
AchR (>0,4nmol/L according to the kit’s instructions) were designated seropositive, and the remaining 
patients were classified as seronegative. 
3.1.2. Peripheral Blood Mononuclear Cells isolation 
Peripheral blood mononuclear cells (PBMCs) were isolated from peripheral blood samples collected in 
EDTA tubes of both healthy subjects and patients with Myasthenia Gravis by Ficoll-PaqueTM density-
gradient sedimentation, as described: Ficoll-PaqueTM Plus reagent was placed into a 50mL conical tube 
and carefully overlaid with 20mL of diluted blood sample (dilution 1:1 in PBS containing 1%FBS) with 
special attention not to mix the two layers. After a centrifugation at 2000rpm for 20 minutes at 20ºC 
in a swinging-bucket rotor without brake, the mononuclear cell layer (interface layer) was carefully 
transferred to a new 50mL conical tube, smoothly ressuspend in PBS containing 1% FBS and then 
centrifuged at 1500rpm for 5 minutes at 4ºC (washing step). The washing step was performed three 
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times. The samples were then transferred to a non-treated T75 flask (Sigma-Aldrich) and incubated 
overnight at 37ºC 5%CO2 in RPMI medium. The PBMCs were counted using a Neubauer Chamber, 
transferred to a 15mL conical tube and centrifuged one last time at 1500rpm for 5 minutes. The 
supernatant was carefully removed and the cell pellet was resuspended in a storage reagent (FBS 
containing 10% DMSO) to a final concentration of [106 cells/mL]. All samples were stored at -80ºC until 
analysis. 
3.2. MIR synthetic peptide 
Based on the literature review mentioned above (Main immunogenic region), the autoantibodies in 
EAMG models recognize a specific region of the alpha1 subunit of the AchR designated Main 
Immunogenic Region with the sequence WNPDDYGGVK. Here, it was intended to confirm if human 
patients with MG produce autoantibodies that recognize the MIR peptide. 
A ten-residue long peptide, designated Main Immunogenic Region (MIR), corresponding to the amino 
acid residues 67-76 (WNPDDYGGVK) of the extracellular domain of the alpha1 subunit of the human 
acetylcholine receptor was commercially synthesized (Thermofisher Scientific – VWR), accordingly to 
what was described in previous studies (Tzartos et al., 1988). 
The lyophilized DNA was dissolved in distilled water to a final concentration of 0,9µg/µL. This peptide 
was assembled containing a fluorescent probe (FICT) and was stored at -80ºC, away from light.  
3.2.1. Screening of serum from patients with Myasthenia Gravis for anti-MIR peptide IgG 
antibodies by an enzyme-linked immunosorbent assay (ELISA)  
An ELISA assay was developed to confirm if the serum from patients with Myasthenia Gravis had 
autoantibodies that would recognize the MIR peptide from the AchR. The ELISA optimization process 
included testing different coating buffers and peptide concentrations, sample dilutions, blocking and 
washing buffers and the conjugated antibody as evidenced in Table 1: 
ELISA step Optimization  
Plates 
Nunc PolySorp, 96-well 
Nunc Immobilizer, solid plate 96-well flat bottom 
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Coating 
MIR peptide: 1,5 μg/mL ; 5 μg/mL ; 10 μg/mL  
Buffer: sodium carbonate pH 9,6 / pH 8,3 / pH 6  
 ethanol 70% 
 Tris-HCl pH 5 / pH 6 / pH 7,5 
Incubation: overnight 4ºC ; 2hours 37ºC 
Samples 
Dilution: 1:20 / 1:50 / 1:100 / 1:200  
PBS 1x containing 1% bovine serum albumin 
Blocking buffer 
PBS 1x containing 1% bovine serum albumin 
PBS 1x containing 3% bovine serum albumin 
PBS 1x containing 5% milk 
Washing buffer 
PBS 1x 
PBS 1x containing 0.05% Tween 20 
Antibody Anti-human IgG 
Conjugated with: Alkaline Phosphatase  
  Horseradish Peroxidase 
Dilution: 1:1000 ; 1:10000 
PBS 1x containing 1% bovine serum albumin 
Table 1 – ELISA optimization 
Conditions and parameters tested to optimize the ELISA protocol. 
The titres of anti-MIR IgG antibodies from both patients with Myasthenia Gravis and controls were 
measured by a final ELISA protocol as follows: Half Nunc 96-well plates (PolySorp) were coated with 
1,5 μg/mL synthesized MIR peptide (ThermoFisher scientific – VWR) diluted in ethanol 70% buffer 
overnight at 4ºC. Subsequently the blocking buffer (PBS 1x containing 3% bovine serum albumin) was 
added and incubated for 1hour at 37ºC. Plasma samples from patients with Myasthenia Gravis and 
healthy subjects, diluted 1:100 in PBS 1x containing 1% bovine serum albumin, were added in 
triplicate to the 96-well plates for 1hour at 37ºC. After washing four times with PBS buffer containing 
0.05% Tween 20, an anti-human IgG (Fc specific)-alkaline phosphatase antibody (Sigma-Aldrich) 
diluted 1:1000 in PBS with 1% bovine serum albumin was added for 1hour. The substrate (4-
Nitrophenyl phosphate disodium salt hexahydrate; Sigma-Aldrich) diluted 1:5000 in BIC buffer (pH 9.8) 
was then added and incubated for 1hour at 37ºC until yielding a yellow colour, and the OD was read in 
a spectrophotometer at 405 nm with reference to 605 nm (Appendix 1 – ELISA method). 
3.2.2. Identification and characterization of the B lymphocyte sub-population with reactivity to 
the MIR peptide in patients with Myasthenia Gravis by flow cytometry  
The acquired PBMCs from both patients with Myasthenia Gravis and healthy controls (see Peripheral 
Blood Mononuclear Cells isolationErro! A origem da referência não foi encontrada.) were incubated 
simultaneously (but separately) for 20 minutes at room temperature, away from light with: 
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a) ‘CD20’ (sample incubated with anti-human CD20 antibody APC-conjugated (Invitrogen)); 
b) ‘MIR’ (PBMCs incubated with MIR peptide commercially synthesised conjugated with FICT); 
c) ‘MIR/CD20’ (double staining); 
A negative control (‘Cells’ – PBMCs without staining) was used in every assay. 
The protocol optimization was required and several dilutions were tested as evidenced in Table 2: 
Staining step Optimization  
Anti-human CD20 antibody APC-conjugated  
(Invitrogen) 
Dilution: 1:500  
   1:1000 
   1:5000  
PBS 1x 
MIR synthetic peptide conjugated with FICT  
(commercially synthesised) 
Dilution: 1:50  
   1:100 
PBS 1x 
Table 2 – Flow cytometry optimization 
Conditions tested to optimize the flow cytometry protocol 
In the optimized final protocol, the dilutions selected to analyse the samples were: anti-human CD20 
antibody APC-conjugated (Invitrogen) diluted 1:1000 in PBS1x buffer and the MIR peptide conjugated 
with FICT diluted 1:50 in PBS1x buffer. 
After 20-minute incubation, 800µL of PBS1x buffer were added to each eppendorf (washing step) and 
the samples were centrifuged at 5000rpm for 2 minutes at room temperature. The supernatant was 
carefully removed and the cell pellet was resuspended in 400µL of PBS1x buffer. 
The samples were analysed in a Flow cytometer (Attune® Acoustic Focusing Cytometer – Applied 
Biosystems) with Attune® Cytometric Software. Cells were gated with a combined live gate, according 
to the scatter characteristics and the dead cells were excluded.  
3.3. Development of a protein composed of the extracellular domain of the alpha 1 subunit of the 
AchR  
The autoantibodies present in patients with MG are biologically active and that the alpha1 subunit is 
the most functionally important subunit of the AchR, it is likely that the antibody target(s) are in this 
subunit, therefore in this task we aimed at synthetizing the isolated extracellular domain of the AchR’s 
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alpha1 subunit (CHRNA1) in order to create a tool for screening the serum of patients with MG for the 
presence of autoantibodies. 
3.3.1. Cloning 1 – CHRNA1 protein  
The protein cloning was performed using specific primers and restriction enzymes (RE), in which the 
sequence corresponding to the extracellular domain of the alpha1 subunit of the human nicotinic 
acetylcholine receptor (Figure 3) was inserted in a specific region of a cloning vector.  
3.3.1.1. Digestion – pT7 Vector 
The digestion protocol followed specific conditions:  
 A total of 20μL of reaction volume was used per 1μg de DNA; 
 1μL of each enzyme was used per 1μg DNA and the enzyme volume never exceeded 10% of 
the final reaction volume; 
 The enzyme buffer represented 10% of the final reaction volume. 
The plasmid chosen for this task was the pT7 (Sigma-Aldrich) which allows the production of the 
protein of interest with a Histidine-TAG. This vector has approximately 5000bp, and contains a gene 
that confers resistance to ampicillin, a multiple cloning site (MCS) with restriction sites for several 
enzymes including the SfiI, and a Histidine TAG plus HA sequence (Appendix 2 – pT7 vector). This 
vector requires the use of E. coli cells containing a source of T7 polymerase, such as BL21 (DE3) cells. 
The vector referred above was digested according to the following protocol: 
Reagents Volume 
Bi-distilled water  35,2 µL 
10x buffer G 6 μL  
Vector (pT7) 12,8 µL 
RE1 (Sfi I) 6 µL 
Reaction volume 60 µL 
Table 3 – pT7 digestion reaction 
The reaction volume was incubated in a thermal cycler at 50ºC overnight. The digestion products were 
separated on a 1% agarose gel containing 0,01% ethidium bromide. DNA loading dye 6x (Fermentas) 
was added to the samples (10% of sample volume) and GeneRuler 1kb Plus DNA ladder (Thermo 
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Scientific) was loaded to one well. The results were visualized and photographed in UV light 
(ChemiDoc - BioRad). 
The products of interest were isolated using the Invisorb® Spin DNA extraction kit (Invitek GmbH, 
Berlin, Germany) according to the manufacturer instructions: resorting to a UV transilluminator, the 
DNA band corresponding to the correct weight of the DNA of interest was excised (minimizing the 
agarose gel slice), placed into a 1,5mL microcentrifuge tube and weighed. Gel Solubilizer S buffer was 
added to the reaction tube containing the DNA-fragment and incubated at 50ºC for 10 minutes until 
the agarose gel slice was completely dissolved. After adding Binding Enhancer buffer the mixture was 
loaded onto the Spin Filter and centrifuged at 11000x g for 2 minutes. The filtrate was discarded and if 
the reaction volume was >800μL (maximum volume of each spin filter column), the centrifugation step 
was repeated. Two washing steps were performed (buffer supplied by the kit) and after discarding the 
flowthrough, a centrifuge step was performed at full speed for 4 minute to remove the residual 
ethanol of the Wash buffer. The Spin Filter was transferred into a new 1,5mL receiver tube and the 
DNA sample eluted with 20μL of MiliQ water. The DNA was quantified using NanoDrop and the 
obtained sample was stored at -20ºC until the DNA/vector binding step.  
3.3.1.2. Digestion – CHRNA1 insert 
The sequence corresponding to the human extracellular domain of the human alpha1 subunit of the 
acetylcholine receptor (CHRNA1) (Figure 3) was commercially assembled (LifeTechnologies) from 
synthetic oligonucleotides and/or PCR products and cloned into a pMA vector (plasmid with ≈3000bp) 
with ampicillin resistance (ampR) using KpnI and SacI cloning sites (Appendix 3 – Synthetic gene 
CHRNA1). The plasmid DNA was purified from transformed bacteria, the concentration determined by 
UV spectroscopy and the final construct was verified by sequencing. 5 µg of the plasmid preparation 
were lyophilized for shipping (LifeTechnologies). The lyophilized DNA was dissolved in 50 µL distilled 
water to a final concentration of 0,1 µg/ µL. 
To obtain the DNA of interest (insert) the above referred plasmid was digested according to the 
following protocol: 
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Reagents Volume  
Bi-distilled water 12 µL 
buffer 10xTango 4 µL  
DNA commertially synthesized 20 µL 
RE1 (EcoRI) 2 µL 
RE2 (NcoI) 2 µL  
Reaction volume 40 µL 
Table 4 – CHRNA1 digestion reaction 
The reaction volume was incubated in a thermal cycler at 37ºC for 4 hours. The products were 
separated on a 1% agarose gel and isolated using the Invisorb® Spin DNA extraction kit (Invitek GmbH, 
Berlin, Germany) according to the manufacturer instructions as mentioned above (see Digestion – pT7 
Vector). The DNA was quantified using NanoDrop and the obtained DNA sample was stored at -20ºC 
until the DNA/vector binding step. 
3.3.1.2.1. CHRNA1 for pT7 vector 
The gene of interest (CHRNA1) digested in the previous step was amplified with specific primers in 
order to be used in a pT7 vector. These primers include restriction sites for the SfiI enzyme 
(underlined): 5’ ATTGCAGTGGCACTGGCTGGTTTCGCTACCGTGGCCCAGGCGGCCTCCGAACATGAGACCCG 
TCTG 3’ (alpha-F-Sfi primer) and 5’ CGGGTATGCGCCATGGTGATGGTGATGGTGCTGGCCGGCCTGGCCGT 
CGGGGC AGCAGGAATA 3’ (alpha-R-Sfi primer).  
The reaction volumes were prepared for DNA amplification accordingly to the following protocol: 
Reagents Positive negative 
Bi-distilled water 20,7 µL 41,5 µL 
10x buffer Reaction 5 µL  5 µL  
Template DNA (150ng) 20,8 µL - 
Alpha-F-Sfi primer (20pmol/μL) 1 µL 1 µL 
Alpha-R-Sfi primer (20pmol/μL) 1 µL  1 µL  
dNTPs Mix (0,5mM) 1 µL  1 µL  
NZYproof DNA polymerase (2,5U/μL) 0,5 µL  0,5 µL  
Reaction volume 50 µL 50 µL 
Table 5 – CHRNA1 amplification reaction 
The reaction volume was incubated in a thermal cycler with the following PCR reaction conditions:  
Cycle step Temperature Time Cycles 
Initial denaturation 95ºC 2 minutes 1 
Denaturing 95ºC 60 seconds 
30 Annealing 58ºC 60 seconds 
Extension 72ºC 50 seconds 
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Final extension 72ºC 10 minutes 1 
Table 6 – PCR amplification conditions 
The products were separated on a 1% agarose gel and the DNA was isolated using the Invisorb® Spin 
DNA extraction kit (Invitek GmbH, Berlin, Germany) according to the manufacturer instructions as 
previously mentioned (see Digestion – pT7 Vector). The DNA was quantified using NanoDrop and the 
samples were stored at -20ºC until the DNA/vector binding step. 
3.3.1.3. CHRNA1-pT7 binding 
Once the vector of interest was opened and the insert was digested, the binding reaction took place. 
First it was necessary to optimize the DNA/Vector proportion, considering the formula: 
 
To bind the CHRNA1 DNA amplified with specific primers to the pT7 vector the reactions were made 
resorting to a kit (Gibson Assembly Master Mix Kit - BioLabs) accordingly to the manufacturer 
instructions, where it was recommended to test the DNA/Vector ratios of 3:1. Using the formula 
previously presented: 
. Ratio 3:1 
 
The reaction volumes were prepared as follows: 
Reagents 
Reactions 
Positive (vector + insert) 
Proportion 3:1 
Negative 
(without insert) 
pT7 vector (50ng) 2,9 µL 2,9 µL 
Insert (21,42ng) 0,2 µL - 
Kit buffer 10 µL 10 µL 
Bi-distilled water 6,9 µL 7,1 µL 
Reaction volume 20µL 20µL 
Table 7 - CHRNA1 binding to pT7 vector according to the kit manufacturer instructions 
The reactions were incubated in a thermal cycler at 50ºC for 15 minutes. The binding reaction 
products were transformed into JM109 bacterial cells by electroporation as follows: 2μL of the binding 
reaction products were transferred to an eppendorf containing JM109 cells, the total volume (cells + 
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DNA) was resuspended and transferred to the electroporation cuvettes and electroporated at 1,8volt 
(Gene Pulser II – Bio-Rad).  500μL of SOC medium were added to the cuvette and resuspended. The 
total volume was transferred to an eppendorf and incubated for 1 hour at 37ºC and 220rpm. The cells 
were plated in LB agar medium with ampicillin and incubated overnight at 37ºC. The plates were 
stored at 4ºC until the screening task.  
3.3.1.4. Screening by PCR 
In the screening protocol for the pT7-CHRNA1 binding, several colonies were selected from the 
ampicillin-LB agar plates and placed in 25μL of sterile water (and stored at 4ºC): 
Reagents positive  
(to each colony selected) 
negative 
Bi-distilled water 36,5 µL 41,5 µL 
10x buffer Reaction 5 µL  5 µL  
Template DNA 5 µL - 
Alpha-F-Sfi primer (20pmol/μL) 1 µL 1 µL 
Alpha-R-Sfi primer (20pmol/μL) 1 µL  1 µL  
dNTPs Mix (0,5mM) 1 µL  1 µL  
NZYproof DNA polymerase (2,5U/μL) 0,5 µL  0,5 µL  
Reaction volume 50 µL 50 µL 
Table 8 – PCR screening reactions 
A PCR similar to the one used in the CHRNA1 DNA amplification was used for the screening step (see 
CHRNA1 for pT7 vector section).  The samples were separated in a 1% agarose gel following the 
protocol as described above. The clones were considered positive if, after PCR screening, was possible 
to see the vector and the insert with the correct molecular weight. 
3.3.1.5. CHRNA1 protein expression assay in BL21 bacterial cells 
From the clones considered positive in “Screening by PCR”, an inoculum was prepared in 7mL of LB 
medium with ampicillin (dilution 1:1000) and incubated overnight at 37ºC at  220rpm. From each 
inoculum a stock of each positive cloned bacteria was stored at -80ºC in a 15% glycerol buffer (using 
1mL of the inoculum) and the DNA was extracted using 3mL of the inoculum per each clone according 
to the manufacturer instructions (Miniprep kit – Nzytech). The DNA was quantified in the NanoDrop.  
The binding products were transformed in BL21(DE3) bacterial cells by electroporation as follows: 2μL 
of binding reaction were transferred to an eppendorf containing BL21(DE3) cells, ressuspended and 
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the total volume (cells + DNA) was loaded to the electroporation cuvettes and electroporation at 
1,8volt (Gene Pulser II – Bio-Rad) was performed.  500μL of SOC medium were added to the cuvette 
and resuspended. The total volume was transferred to an eppendorf and incubated for 1 hour at 37ºC 
and 220rpm. The cells were plated in LB agar medium with ampicilin and incubated overnight at 37ºC. 
One bacterial colony from each positive clone was selected from the plates and placed in separated 
tubes with approximately 5 mL of SB medium with ampicillin (dilution 1:1000) at 37ºC at 220rpm for 
16-18h (plates were stored at 4ºC). An inoculum from each clone was incubated at 37ºC at 220rpm 
until optimal optical density was achieved (0,8-0,9). Subsequently cell growth was stopped on ice. 
Protein expression was induced with IPTG 1mM and the cultures were incubated for 3hours at 
200rpm at 37ºC. After the protein expression the culture volumes were centrifuged at 4000rpm for 5 
minutes and the pellet stored at -20ºC until protein purification. 
3.3.1.5.1. Screening of CHRNA1 protein expression 
The pellet obtained in the preceding step was resuspended in 400μL of PBS buffer with antiprotease 
freshly prepared (Roche). The samples were placed in a sonicator for 30 minutes and then centrifuged 
at 1200rpm for 10 minutes at 4ºC. The soluble fraction was tested in an ELISA assay to assess the 
protein expression: a polysorp 96-well plate (Nunc) was coated with 100μL of the soluble fraction 
obtained from each clone, for 1hour at 37ºC. After washing the wells with 200μL of PBS 1x buffer 
three times, 100μL of blocking buffer (PBS 1x buffer containing 3% albumin) was added to each well 
and incubated for 1 hour at 37ºC. Anti-HA antibody conjugated with HorseRadish Peroxidase (HRP) 
was added (dilution 1:1000 in PBS buffer) and incubated for 1hour at 37ºC. Finally ABTS + H2O2 
(1000:2) was added and the plate was incubated at room temperature until yielding colour 
(approximately 10 minutes) and the optical density (OD) was read in a spectrophotometer at 405 nm 
with reference to 492 nm. 
In addition to this ELISA expression assay, a western blot was performed to confirm the protein 
expression. The protocol was equal to the one described in “Screening of fusion protein expression” 
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but the antibody used in this case was anti-HA antibody conjugated with HorseRadish Peroxidase 
(HRP). 
The clones that expressed the protein of interest were sent for sequencing (at Macrogen). Once the 
DNA sequence was confirmed to be exactly the same as the one from the original gene of CHNRA1, 
the protein expression was optimized to be performed in larger amounts.  
The expression conditions tested were: 6h of incubation at different temperatures: 16ºC, 20ºC and 
30ºC and agitation: 200rpm and 140rpm. After the protein expression, each culture volume was 
centrifuged at 4000rpm for 5 minutes and the pellet was stored at -20ºC until the protein purification 
step. Each pellet was resuspended in PBS buffer containing antiprotease (Roche), placed in a pulse 
sonicator for 20 minutes and centrifuged at 10000rpm for at least 2 hours at 4ºC. The soluble fraction 
was used to test the protein expression conditions. 
The protein expression was verified by electrophoresis: protein samples obtained from bacterial 
culture from each expression conditions tested were mixed with 4x Protein Loading buffer, denatured 
for 10 minutes at 95ºC and separated in a 10% SDS-polyacrylamide gel. After running the gel at 20mA 
for approximately 100 minutes, the system was tuned off, disassembled, the gel was removed 
(stacking gel was cut off and discarded) and stained with Coomassie Blue for 30 minutes. Distaining 
buffer (40% distilled water, 10% acetic acid and 50% methanol solution) was added and incubated 
overnight with agitation.  
The Coomassie Blue staining analysis allowed defining the best conditions for protein expression, 
concluding that the optimized conditions for protein expression of a 2L bacterial culture (in a 5L 
Erlenmeyer for better ventilation) after IPTG induction, for the selected clone were 6h at 30ºC with 
agitation at 140rpm.  
3.3.1.5.2. Purification of CHRNA1 protein 
The CHRNA1 protein produced by cloning was purified by affinity chromatography using HIS-Trap 
columns (GE Healthcare), since the resulting protein has an 8-histidine fragment at its end.  
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Briefly, the sample was loaded into the chromatography columns under specific conditions that favour 
the binding of the protein to the complementary substance present in the column matrix. Changing 
the conditions (by adding a competitive ligand or altering the pH, ionic strength or polarity) was 
possible to elute the protein of interest apart from the other proteins.  
According to the manufacturer instructions it is recommended to test a gradient of imidazole 
concentration in protein binding and elution buffers (20mM sodium phosphate, 500mM of sodium 
chloride, 10 to 500mM of imidazole in 1L; pH7,4 adjusted with hydrochloric acid and filtered through a 
0,45μm filter) to optimize the conditions to separate the protein of interest from other proteins 
existent in the bacterial cultures. In the binding buffer the concentrations of 20mM and 40mM of 
imidazole were used and for the elution buffer a gradient of imidazole was used: 40mM; 60mM; 
100mM; 140mM; 200mM and 500mM. Each fraction passing through the column was collected and 
separated on a 10%SDS-polyacrimalide gel later stained with Coomassie Blue.  
3.3.2. Screening of serum from patients with Myasthenia Gravis for anti-CHRNA1 protein IgG 
antibodies by an enzyme-linked immunosorbent assay (ELISA)  
In this task, the indirect ELISA assays were used to confirm if patients with MG had autoantibodies that 
recognized the CHRNA1 protein obtained in the “Cloning 1 – CHRNA1 protein” task. After optimization 
(coating buffers tested: PBS 1x; BIC and ethanol 70% - and protein concentration tested: 10μg/mL and 
5μg/mL), the protocol used (similar to the one previously described in Screening of serum from 
patients with Myasthenia Gravis for anti-MIR peptide IgG antibodies by an enzyme-linked 
immunosorbent assay (ELISA)) was the following: half Nunc 96-well plates (PolySorp) were coated with 
5μg/mL CHRNA1 protein diluted in ethanol 70% overnight at 4ºC. Subsequently, blocking buffer (PBS 
1x containing 3% bovine serum albumin) was added and incubated for 1hour at 37ºC. Plasma samples 
from patients with Myasthenia Gravis and healthy subjects, diluted 1:100 in PBS 1x containing 1% 
bovine serum albumin, were added to triplicate wells to the 96-well plates for 1hour at 37ºC. After 
washing four times with PBS buffer containing 0.05% Tween 20, anti-human IgG (Fc specific)-alkaline 
phosphatase antibody (Sigma-Aldrich) diluted 1:1000 in PBS with 1% bovine serum albumin was added 
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for 1hour. Substrate (4-Nitrophenyl phosphate disodium salt hexahydrate; Sigma-Aldrich) diluted 
1:5000 in BIC buffer (pH 9.8) was added and incubated for 1hour at 37ºC until yielding a yellow colour 
development and the OD was read in a spectrophotometer at 405 nm with reference to 605 nm. 
3.4. Development of a fusion protein composed of the extracellular domain of the alpha 1 subunit of 
the AchR and the Fc region of a immunoglobulin 
This assignment aimed at creating a fusion protein constituted by the extracellular domain of the 
alpha1 subunit of the AchR (CHRNA1), and the Fc region of an IgG immunoglobulin to create a tool 
that would allow the identification of autoantibody-producing B-cells in patients.  
3.4.1. Cloning 2 – fusion protein  
3.4.1.1. Digestion – pFUSE-hIgG1e1-Fc2 Vector 
This digestion protocol followed the specific conditions of the ones described previously for the 
Digestion – pT7 Vector. 
The plasmid used in this task was the pFUSE-hIgG1e1-Fc2 (Invivogen) which allows the secretion of 
proteins fused to an immunoglobulin's Fc-domain. This vector has approximately 4197bp and includes: 
an IL2 signal sequence (IL2ss) to create Fc-fusion proteins from proteins that are not naturally 
secreted, the Sh ble gene (from Streptoalloteichus hindustanus) that confers resistance to Zeocin, and 
a multiple cloning site (MCS) with the restriction sites for several enzymes including the EcoRI and the 
NcoI (Appendix 4 – pFuse-hIgG1e1-Fc2 vector). 
The above referred plasmid was digested according to the following protocol: 
Reagents Volume 
Bi-distilled water  41,5 µL 
buffer 10xTango 6 μL  
Vector (pFuse-hIgG1e1-Fc2) 6,5 µL 
RE1 (EcoRI) 3 µL 
RE2 (NcoI) 3 µL 
Reaction volume 60 µL 
Table 9 - pFuse-hIgG1e1-Fc2 digestion reaction 
The reaction volume was incubated in a thermal cycler at 37ºC for 4 hours. The products were 
separated on a 1% agarose gel and the DNA was isolated using the Invisorb® Spin DNA extraction kit 
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(Invitek GmbH, Berlin, Germany) according to the manufacturer instructions and as previously 
described (see Digestion – pFUSE-hIgG1e1-Fc2 Vector). The DNA was quantified using NanoDrop and 
the obtained samples were stored at -20ºC until the DNA/vector binding step. 
3.4.1.2. CHRNA1 for the pFUSE-hIgG1e1-Fc2 vector 
The sequence corresponding to the human extracellular domain of the alpha1 subunit of the 
acetylcholine receptor (CHRNA1) was previously digested and separated from its original plasmid in 
the Digestion – CHRNA1 insert task. In this task the DNA purified from the agarose gel as described 
before was used. The DNA was quantified using NanoDrop and the obtained sample was stored at -
20ºC until the DNA/vector binding step. 
3.4.1.3. CHRNA1-pFUSE-hIgG1e1-Fc2 binding 
To optimize the DNA/Vector proportion we considered the following formula: 
 
It was recommended to test the DNA/Vector with ratios of 3:1 and 5:1. Using the formula previously 
presented: 
. Ratio 3:1 
 
. Ratio 5:1 
 
The pFUSE-hIgG1e1-Fc2 – CHRNA1 binding reactions were made as follows: 
Reagents 
Reactions 
Positive (vector + insert) 
Proportion 3:1 
Negative 
(without insert) 
Positive (vector + insert) 
Proportion 5:1 
pFUSE vector (40ng) 1,1 µL 1,1 µL 1,1 µL 
Insert 2,7 µL - 4,5 µL 
10x buffer R 2 µL 2 µL 2 µL 
T4 DNA ligase 0,2 µL 0,2 µL 0,2 µL 
Bi-distilled water 14 µL 16,7 µL 12,2 µL 
Reaction volume 20µL 20µL 20 µL 
Table 10 - pFUSE-hIgG1e1-Fc2 – CHRNA1 binding reactions 
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The mixtures were incubated in a thermal cycler at 22ºC for 2 hours plus 5 minutes at 70ºC (to 
inactivate the T4 DNA ligase enzyme). The reaction tubes were kept at 4ºC until use (maximum 24 
hours).  
1μL of the DNA extracted from each clone was transformed into JM109 bacterial cells and plated in LB 
agar plates with the selective antibiotic (Zeocin), using the same protocol as the one described above 
(CHRNA1-pT7 binding). 
3.4.1.3.1. Screening by alkaline lysis 
A screening step performed by alkaline lysis was necessary to verify if the bacterial colonies that grew 
in the Zeocin-LB agar plate had the correct DNA sequence. To perform this protocol it was necessary 
to prepare three different lysis solutions: 
Lysis 
solution  
Reagents Recipe  Storage 
I 
10mM EDTA (pH 8)  
50mM glucose 
25mM Tris-HCl (pH 8) 
100mL Tris-HCl: 0,30g Tris + 90mL H2O, pH adjusted with HCl, 
final volume completed to 100mL with MiliQ water;  
The solution was autoclaved; 
2mL of 10mM EDTA (pH 8) and 0,99g of glucose were added. 
4ºC  
II 
0,2N NaOH  
1% (p/v) SDS 
 
10mL: 0,10g SDS + 400 μL NaOH 5N; final volume completed 
to 100mL with MiliQ water; 
Freshly 
prepared; 
Kept at 4ºC 
III 
5M potassium 
acetate 
Acetic acid 
100mL: 60mL of 5M potassium acetate, 11, 5mL of acetic acid 
and 28,5mL of MiliQ water  
 
4ºC 
Table 11 – Lysis solutions for alkaline lysis 
HCl = hydrochloric acid; SDS = Sodium Dodecyl Sulphate; NaOH = Sodium Hydroxide 
Some positive and, at least, one negative bacterial colonies were selected from the plates and placed 
in separated tubes with approximately 5mL of LB medium with zeocin at 37ºC at 220rpm for 16-18 
hours (plates were stored at 4ºC). Afterwards 1,5mL of each inoculum was transferred to an 
eppendorf and centrifuged at 1300rpm for 5 minutes at 4ºC (the remaining inoculum was stored at 
4ºC). The supernatant was discarded and the pellet was resuspended in 100μL of Lysis solution I. 
200μL of lysis solution II (freshly prepared) was added and tubes were gently mixed by inversion. After 
5-minute incubation on ice, 150μL of lysis solution III were added to each tube and mixed by inversion. 
The volume was incubated for 5 minutes on ice and then centrifuged at 1300rpm for 5 minutes at 4ºC. 
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The supernatant was transferred to a new eppendorf and the DNA precipitation was performed with 
ethanol as follow: 1mL of absolute ethanol was added to each tube and mixed carefully, incubated for 
2 minutes at room temperature and centrifuged at 1300rpm for 5 minutes at 4ºC. The supernatant 
was removed by inverting the tube and 1mL of ethanol 70% was added and mixed by carefully 
inverting the tube 4 times. After centrifugation at 1300rpm for 2 minutes at 4ºC the supernatant was 
removed by aspiration, the pellet was dried up at room temperature and resuspended in 40μL of 
sterile MiliQ water. The DNA was quantified in the NanoDrop and the products were stored at -20ºC. 
The DNA isolated from the selected colonies was digested using the same protocol as before (in 
Digestion – pFUSE-hIgG1e1-Fc2 Vector):  
Reagents Volume  
Bi-distilled water 12 µL 
buffer 10xTango 2 µL  
Clones’ DNA purified by alkaline lysis 5 µL 
RE1 (EcoRI) 0,5 µL 
RE2 (NcoI) 0,5 µL  
Reaction volume 20 µL 
Table 12 – Clones’ DNA digestion reactions 
The reaction volume was incubated in a thermal cycler at 37ºC for 12 hours. The products were 
separated on a 1% agarose gel containing 0,01% ethidium bromide. DNA loading dye 6x (Fermentas) 
was added to the samples (10% of sample volume) and GeneRuler 1kb Plus DNA ladder (Thermo 
Scientific) was loaded to one well. The results were visualized and photographed in UV light 
(ChemiDoc - BioRad). The clones were considered positive if, after digestion and separation in the 
agarose gel, was possible to see the vector and the insert with the correct molecular weight. 
3.4.1.4. CHRNA1-Fc fusion protein expression assay by calcium phosphate transfection  
When working with mammalian cells special concerns ought to be considered. These cells have a 
doubling time of 12 to 48 hours being susceptible to contamination by bacteria and fungi therefore 
specific sterile conditions and procedures were carefully maintained during all assays.  
A calcium phosphate transfection protocol was performed to express the protein of interest. In this 
technique the DNA was endocytosed (by uncharacterized pathways) into HEK-293T cells (Human 
Embryonic Kidney cell line), following a chemical environment that results in the DNA attachment to 
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the cell surface (Kingston, 2003). This technique is commonly used with adherent cells to produce stable 
integrated DNA transfections and tends to be more efficient in the production of fusion proteins in 
stable cell-lines than other types of transfection such as DEAE-dextran-mediated transfection.  
The transfection protocol was performed as described: HEK-293T  cells were plated in a 6-well plate at 
a concentration of 5 x 105 cells/well in 2mL of DMEM medium (Sigma-Aldrich) supplemented with 10% 
Fetal Bovine Serum (FBS) (ThermoScientific) and incubated at 37ºC, in an atmosphere of 95% air and 
5% CO2 at saturating humidity for 16-18 hours. 
To perform this protocol it was necessary to prepare two solutions: “Mix A”, which contains Tris-
Borate-EDTA (TBE) buffer, the DNA of interest (DNA recovered from all positive clones selected in the 
previous task – Screening by alkaline lysis) and calcium chloride (CaCl2) 2,5M buffer, and “Mix B” that 
consists in Hepes Buffered Saline (HBS) 2x. These mixes were freshly prepared per each well, using the 
sterilized stock solutions of TBE 5x buffer (54g Tris-Base; 27,5g of boric acid (H3BO3); 20mL EDTA 0,5M; 
distilled water till 500mL; pH 7,6) and HBS 2x buffer (8g of sodium chloride (NaCl); 0,2g of disodium 
phosphate heptahydrate (Na2HPO4-7H2O); 6,5g HEPES; distilled water till 500mL; pH 7): 
Mix  Reagents Recipe Sterilization Storage 
A 
TBE buffer,  
5μg of DNA  
CaCl2 2,5M buffer 
Per well: TBE buffer up to 250 μL, 
DNA and 25 μL of CaCl2 2,5M buffer, 
following this exact order 
Buffers  
sterilized by 
filtration with 
0,2μm filters 
Room 
temperature  
B HBS 2x Per well: 250 μL of HBS 2x 
Room 
temperature 
Table 13 – Mixes ‘A’ and ‘B’ for calcium phosphate transfection 
“Mix A” was carefully added to the “Mix B” in continuous agitation (vortex) and incubated for 30 
minutes at room temperature. Subsequently the mixes were added dropwise to each well and plates 
were incubated 24 hours at 37ºC in an atmosphere with 5% CO2. 
24 hours after the transfection the medium was removed from the plates and substituted by DMEM 0 
medium (without FBS since it affects protein purification) and incubated for 48 hours at 37ºC in an 
atmosphere with 5% CO2. After 48 hours the supernatant was removed and stored at -80ºC until 
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protein purification. A negative (without DNA) and a positive (DNA known to be expressing a protein 
with the same molecular weight as the fusion protein tested) control were included in every step.  
3.4.1.4.1. Screening of fusion protein expression  
A Western immunoblotting technique was used to screen the fusion protein expression of each clone 
selected in the previous task. 
An electrophoresis system was assembled and the running buffer (25mM Tris Base 3,02g; 192mM 
Glycine 14,42g; 0,1% SDS 1g; distilled water 1L) was prepared. The protein samples (supernatant 
collected after calcium transfection) were mixed with 4x Protein Loading buffer (10% (w/v) of SDS; 
10% of beta-mercaptoethanol; 30% (w/v) of glycerol; 0.05% of bromophenol blue and 240mM Tris-HCl 
pH 6.8), denatured for 10 minutes at 95ºC and separated by 10% SDS-polyacrylamide gel. After 
running the gel at 20mA for approximately 100minutes, the system was tuned off, disassembled, and 
the gel was removed (stacking gel was cut off and discarded) to transfer the proteins to a 
nitrocellulose membrane. 
To do so a wet transfer protocol was performed: two sheets of Whatman 3MM filter paper and one 
sheet of transfer nitrocellulose membrane were cut to the size of the gel and immersed in the transfer 
buffer (25mM Tris Base 3,02g; 192mM Glycine 14,42g; 20% methanol 200mL; dH2O 1L). The transfer 
"sandwich" was assembled by placing, from the negative electrode to the positive electrode, the 
following items: sponge; filter paper sheet; SDS gel; nitrocellulose membrane; filter paper sheet; 
sponge. After ensuring that no air bubbles have been formed between the gel and membrane, the 
sandwich cassette was closed, the sandwich was placed in the transfer tank (containing the transfer 
buffer) with the membrane side closest to the positive electrode (red lead) and the running conditions 
were settled (400mA for 90 minutes). To verify the success of the wet transfer, the membrane was 
stained with Ponceau Red buffer for 10 minutes.  
After washing the membrane with TBS buffer (50mM Tris-HCl, pH 7.4, 150mM NaCl) containing 0,1% 
of Tween 20 for 10 minutes, the blocking solution (TBS-0,1%T containing 3% nonfat dry milk) was 
added and the membrane was incubated with continuous agitation overnight at 4ºC to prevent non-
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specific background binding. An anti-IgG antibody conjugated with HorseRadish Peroxidase (HRP) was 
added to the membrane (dilution 1:1000 in blocking solution) and incubated for 3 hours at room 
temperature with continuous agitation. The membrane was washed 3x 15 minutes with TBS-0,1%T 
and the immobilon western chemiluminescent HRP substrate was added and incubated for 5 minutes. 
The detection of antibody binding was done using chemiluminescence high sensitive light (ChemiDoc – 
BioRad).  
The clones confirmed to be expressing the fusion protein were sent for sequencing (at Macrogen) to 
assure that the DNA sequence was correct. 
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4. Results  
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4.1. Screening of serum from patients with Myasthenia Gravis for anti-MIR peptide IgG antibodies 
Patients with MG and anti-AchR antibodies (seropositive patients) do not have titters of antibodies 
that recognize the WNPDDYGGVK synthetic peptide significantly different from those detected in 
healthy controls or seronegative patients (Figure 5). 
 
Figure 5 – Optical Density values of Myasthenia Gravis patients and controls when tested for the presence of anti-MIR peptide 
antibodies by ELISA assay 
 
4.2. Identification and characterization of the B lymphocyte sub-population responsible for the 
production of autoantibodies in patients with Myasthenia Gravis 
The peripheral blood mononuclear cells (PBMCs) isolated from the peripheral blood samples of both 
healthy subjects and patients with MG was used in this task (isolation procedure described above in 
Peripheral Blood Mononuclear Cells isolation). The samples from patients with MG treated with 
Rituximab were collected after 3 month of the last administration to eliminate possible bias associated 
with the drug regarding the circulating B lymphocytes. 
a)  Anti-human CD20 antibody APC-conjugated 
In this task it was aimed to detect the CD20 membrane associated phosphoprotein that is present in 
the surface of every B-cell (except stem cells, pro-B-cells and effector B-cells) in order to distinguish 
the plasma cells involved in the production of the pathogenic antibodies: long-term plasma cells 
(CD20-) and short-term plasma cells (CD20+).  
An increase in the concentration of the anti-human CD20 antibody APC-conjugated (Invitrogen) was 
proportional to the mean fluorescent intensity (MFI) detected in each sample (Figure 6).  
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Figure 6 – Dilutions tested for anti-human CD20 antibody APC-conjugated 
Comparison of the three dilutions tested for B lymphocyte detection by probing with anti-CD20 antibody. A control sample 
(without the probe) was used to determine the baseline fluorescence. 
b) MIR synthetic peptide FICT-conjugated 
The optimal condition of the MIR synthetic peptide was determined  using only PBMCs samples from 
patients since it was not expected that this peptide would be recognized by B-cells from healthy 
controls. 
 
Figure 7 - Dilutions tested for MIR synthetic peptide FICT-conjugated 
Dot plot graphic of the dilutions tested to detect B lymphocytes that recognized the MIR peptide. A control sample (without 
the probe) was used to determine the baseline fluorescence that is not due to the probe used in the MIR synthetic peptide 
(represented in red); in purple is represented the 1:100 dilution of the MIR peptide and in blue is the 1:50 dilution. 
The lymphocytes present in the sample of one patient with MG recognized the MIR synthetic peptide 
in a concentration dependent fashion (Figure 7).  
c) CD20/MIR (double staining) 
In order to characterize the B lymphocytes responsible for the production of these antibodies we 
double stained the PBMCs samples from patients and healthy controls with the MIR synthetic peptide 
and anti-CD20 antibody. 
The gates were defined considering the lymphocyte cell population and controls without probes were 
included in every assay. There were no differences between seropositive patients (patients whose 
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autoantibodies recognize the AchR) and seronegative patients and furthermore, the data showed that 
the lymphocyte population selected from the healthy controls was also positive for the MIR peptide 
with the majority of the cells being positive for the MIR peptide suggesting that the recognition of the 
MIR peptide was unspecific (Figure 8). 
 
Figure 8 – CD20/MIR double staining in a healthy control sample 
 
4.3.  Development of a protein composed of the extracellular domain of the alpha 1 subunit of the 
AchR 
4.3.1. Cloning 1 – CHRNA1 protein 
4.3.1.1. Digestion – pT7 vector  
The pT7 vector was digested using the SfiI restriction enzyme and separated in a 1% agarose gel and 
the results were visualized and photographed in UV light (ChemiDoc - BioRad):  
 
Figure 9 – pT7 vector digestion with SfiI restriction enzyme 
This agarose gel image shows the open pT7 vector with a molecular weight of ≈5000bp. 
The vector used in this task had approximately 5000bp and after the digestion with SfiI restriction 
enzyme was possible to see a band at a higher molecular weight corresponding to the opened vector 
and a band at a lower molecular weight (below the 500bp ladder mark) corresponding to segment 
that was excised with the digestion of the vector (Figure 9).  
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4.3.1.2. Digestion – CHRNA1 insert 
The extracellular domain of the alpha 1 subunit of the nicotinic acetylcholine (CHRNA1) receptor was 
commercially synthesised and cloned into a pMA vector (a plasmid with ≈3000bp). Figure 10 shows 
the agarose gel where the DNA of interest was separated from its vector after the digestion with the 
same restriction enzymes as the vector in the previous task (EcoRI and NcoI). The band at the bottom 
of the agarose gel (approximately 681bp) matches the molecular weight of the DNA of interest 
(accordingly to the document provided by LifeTechnologies containing the plasmid information). 
Separated from the region of interest, at the top of the agarose gel with higher molecular weight 
(≈2400bp), is the open plasmid band. 
 
Figure 10 – CHRNA1 digestion with EcoRI and NcoI restriction enzymes 
This agarose gel image  shows the CHRNA1 band at the bottom of the image (on the right side) with a lower molecular weight 
(≈681bp) and a band at approximately 2400bp corresponding to opened plasmid into which the CHRNA1 was cloned at Life 
technologies in vector’s digestion. 
4.3.1.2.1. CHRNA1 for pT7 vector 
The gene of interest (CHRNA1) digested in the previous step was amplified with specific primers, that 
include the restriction sites for SfiI enzyme. In this reaction a negative control (without template DNA) 
was used.  
The agarose gel image obtained after the DNA amplification showed that in the positive reactions 
(with the template DNA) there was a brighter band, near the 750bp ladder band, that corresponded to 
the CHRNA1 molecular weight (681bp) plus the two primers, making the final molecular weight slightly 
higher than the CHRNA1 gene alone. It is also possible to see a band at 500bp that might indicate 
unspecific binding or an incomplete amplification and for that reason these bands were not excised 
for DNA purification. Additionally, a band with a significant lower weight than 250bp was present in 
every well (either in the positive or in the negative) which could represent the unbounded primers 
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used for CHRNA1 gene amplification, since in the negative control this was the only band that 
appeared in the agarose gel (Figure 11). 
 
Figure 11 – Amplified CHRNA1 DNA using specific primers 
In the positive wells was possible to see the amplified CHRNA1 DNA and in both positive and negative control wells the band 
at the bottom of the image corresponds to the primer used in this task that did not bound to the CHRNA1 DNA. 
4.3.1.3. Screening of CHRNA1-pT7 binding 
After the binding of the open pT7 vector to the amplified CHRNA1 with SfiI restriction sites, the 
resulting DNA was transformed into JM109 E. coli bacterial strains and plated in an ampicillin selective 
LB-agar plate. The plates used for bacterial colonies growth were: A) plate with the DNA/Vector ratio 
3:1 and B) negative control (without CHRNA1 DNA). Twenty seven bacterial colonies were chosen for 
screening by PCR and the DNA isolated was screened using a similar protocol as in CHRNA1 DNA 
amplification (see CHRNA1 for pT7 vector) and then separated in an agarose gel.  
Considering that the screening by PCR was a procedure similar to the one already used, it was 
expected that the results obtained were similar to the ones before.  
 
Figure 12 – Screening of CHRNA1-pT7 binding  
This agarose gel represents part of the tested colonies for CHRNA1-pT7 binding where it was possible to see that only three 
of seven tested colonies in this gel were positive for the CHRNA1 DNA. 
Some of the bacterial colonies selected for screening had the CHRNA1 DNA integrated in the vector 
(Figure 12).In the presence of specific primers, the CHRNA1 DNA was amplified obtaining an analogous 
image as to the one shown in Figure 11: a band near the 750bp ladder band that corresponded to the 
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CHRNA1 molecular weight (681bp) plus the two primers used and a band of the unbounded primers at 
a very low molecular weight (under 250bp). 
From the 27 tested colonies for CHRNA1-pT7 binding only seven were considered positive and chosen 
for protein expression. 
4.3.1.4. Screening of CHRNA1 protein expression assay  
The screening for the CHRNA1 protein ((MW± 30kDa) was performed by two different procedures: an 
ELISA and a western blot. The first assay was used to assess the protein expression while the western 
blot was used to confirm if the protein expressed had the correct molecular weight. The optical 
densities (OD) obtained with the ELISA method (data not shown) revealed that all clones tested 
expressed the CHRNA1 protein. The disparity in the optical densities suggested differences in the 
expression rates between clones however these data by themselves were not definitive, requiring 
another technique to confirm them.  
The western blot was performed using x-ray film exposure. This technique rapidly exposes the film to 
saturation allowing the detection of weakly expressed proteins that would not be detected in 
chemiluminescent imaging.  
Four of the clones tested are represented in Figure 13 in which the negative control (second well to 
the left) had no protein expression and the positive control expressed the 35kDa protein as expected.  
The clones were considered positive if after revelation and imaging was possible to see a clear band at 
the correct molecular weight. Only two of the clones tested for the CHRNA1 protein expression were 
considered to be positive and sent for sequencing in order to confirm that the DNA sequence was 
exactly the same as the one from the original gene of CHNRA1.  
 
Figure 13 – Screening of CHRNA1 protein expression in the selected clones by western blot 
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These western blot film shows that only one of the four tested clones here expressed the CHRNA1 protein. Both negative 
(without IPTG induction) and positive (protein expressed at 35kDa) controls were included.  
The fact that there was the need to resort to a much more sensitive imaging technique to detect the 
protein bands suggests that the conditions used in the protein expression assay were not the best 
ones. 
4.3.1.4.1. Purification of CHRNA1 protein 
After confirmation of correct sequence we began the purification by affinity chromatography 
following a standard protocol. The CHRNA1 protein was not isolated from other proteins present in 
the bacterial culture, and these were being eluted at the same time, suggesting that the buffers used 
for binding and elution were not effective and the CHRNA1 protein did not bound to the Nickel-
Sepharose beads of the HIS-Trap columns.  
4.3.2. Measurement of anti-CHRNA1 IgG antibodies 
Although the CHRNA1 protein had not been purified, it would still be the proposed target for the 
autoantibodies associated with MG. Therefore, we assessed the serum from patients with MG for 
antibodies that would recognize the protein. Samples with OD values of 3 standard deviations (SD) 
above the mean of the healthy controls were considered to be positive.  
We found a significant difference between the titres of anti-CHRNA1 protein in patients when 
compared with controls (p value=0,031). Furthermore, ≈50% of the patients with anti-AchR antibodies 
(seropositive patients) were positive for antibodies that recognized the CHRNA1 protein (Figure 14). 
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Figure 14 - Optical Density values of patients with Myasthenia Gravis and controls when tested for the presence of anti-
CHRNA1 antibodies by an ELISA assay 
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50% of the patients tested recognized the CHRNA1 protein (antibodies titres cut-off defined by mean) (p value=0,0316). 
Patients highlighted in blue besides the immunosuppressive therapy were also treated with Rituximab.  
All patients enrolled in this study were being treated with corticosteroids and immunosuppressive 
drugs, such as prednisolone and azathioprine. However some patients were also treated with 
Rituximab. The patients treated with Rituximab had lower values of anti-CHRNA1 antibodies (p 
value=0,1) (Figure 15). This finding can be explained as Rituximab is extremely effective in depleting 
the circulating B lymphocytes and therefore these patients could have a decrease in the production of 
the antibodies. Nevertheless, the number of patients collected in this group is very small and 
therefore, the interpretation of these results should be careful. 
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Figure 15 - Optical Density values of seropositive patients with MG treated with and without Rituximab when tested for the 
presence of anti-CHRNA1 antibodies by an ELISA assay 
The seropositive patients treated with Rituximab had lower values of anti-CHRNA1 antibodies (p value=0,1).  
 
4.4. Development of a fusion protein composed of the extracellular domain of the alpha 1 subunit of 
the AchR and the Fc region of a immunoglobulin 
4.4.1. Cloning 2 – fusion protein 
4.4.1.1. Digestion – pFUSE-hIgG1e1-Fc2 Vector 
The pFUSE-hIgG1e1-Fc2 vector was digested using the restriction enzymes EcoRI and NcoI. The results 
were visualized and photographed in UV light (ChemiDoc - BioRad) (Figure 16).  
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Figure 16 – pFUSE-hIgG1e1-Fc2 vector digestion with EcoRI and NcoI restriction enzymes  
Agarose gel image that shows the vector with a higher molecular weight (4197bp) above the ladder band at 3000b, and a 
band at approximately 900bp corresponding to region that was excised in vector’s digestion. 
This figure shows a band matching the molecular weight of the vector at the top of the agarose gel, 
since the vector has 4197bp, which was separated from the region excised when the vector was 
digested with the restriction enzymes EcoRI and NcoI (band at approximately 900bp). 
4.4.1.2. Screening of CHRNA1-pFUSE-hIgG1e1-Fc2 binding  
The opened vector and the CHRNA1 DNA were fused together with a specific enzyme (T4 DNA ligase), 
transformed into JM109 bacterial cells and plated in an antibiotic selective LB-agar plates: the plate A 
(DNA/Vector ratio 3:1) had several isolated colonies; plate B (DNA/Vector ratio 5:1) had small bacterial 
colonies filling the plate, making impossible to isolate one colony; the negative control (plate C) had 
no colonies. The plate selected to screen the CHRNA1-pFUSE-hIgG1e1-Fc2 binding was the one with 
the DNA/Vector ratio of 3:1. Fourteen of those colonies were used for alkaline lysis and the DNA 
isolated was digested using the same protocol as in Digestion – pFUSE-hIgG1e1-Fc2 Vector and then 
separated in an agarose gel. 
 
Figure 17 – Screening of CHRNA1–pFUSE-hIgG1e1-Fc2 binding 
In this agarose gel was possible to see some of the colonies tested for the CHRNA1 - pFUSE-hIgG1e1-Fc2 binding. Beneath 
the ladder band that corresponds to the 5000bp molecular weight it was possible to observe one band in each well 
(matching the pFUSE-hIgG1e1-Fc2 vector weight) and at the bottom the CHRNA1 band with a lower molecular weight 
(≈681bp). 
Some of the colonies tested and separated in the agarose gel are represented in Figure 17. The pFUSE-
hIgG1e1-Fc2 vector band appeared in every tested bacterial clone slightly below the ladder band that 
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marks the molecular weight of 5000bp, since the vector has 4197bp.The bottom of the gel shows the 
bands matching the molecular weight of the CHRNA1 (≈681bp). In some wells, such as the third and 
fifth wells of this gel, it was possible to see two extra bands: one at approximately at 1000bp of 
molecular weight and another one underneath the band that corresponds to the digested vector, 
these bands may indicate a non-completed digestion of the DNA isolated in the alkaline lysis task or an 
incorrect binding of CHRNA1 DNA to the pFUSE-hIgG1e1-Fc2 vector thus these clones were not 
chosen for the protein expression assays.  
4.4.1.3. Screening of fusion protein expression 
The previous task allowed the selection of six clones to express the fusion protein using calcium 
phosphate transfection after which the supernatant was collected and the protein expression was 
assessed by Western Blot.   
The fusion protein was expected to have approximately 55kDa (the molecular weight of the CHRNA1 
protein – ≈30kDa – plus the Fc domain of the immunoglobulin), hence the positive control used was a 
DNA that expresses a protein with the same molecular weight as the tested fusion protein. 
Additionally, a negative control (without DNA) was included in the transfection to rule out the 
possibility that another protein could be expressed or present in the supernatant with the same 
molecular weight as the fusion protein.  
Some of the clones tested are represented in the figure below (Figure 18): the two positive controls 
expressed the protein at 55kDa and the negative control did not express any protein as was expected. 
The image shows that only one of the four clones tested expressed the fusion protein and did so at a 
very low rate.  
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Figure 18 – Screening of fusion protein expression in selected clones 
These western blot results showed that only one of the four tested clones here expresses the fusion protein. Negative 
(without DNA) and positive (DNA known to be expressing a protein with the same molecular weight as the fusion protein 
tested) controls were included. 
Three clones confirmed to be expressing the fusion protein and were sent for sequencing to confirm if 
the DNA sequence was the correct one.  
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5. Discussion 
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The MIR peptide was described as the major antigen in an animal model of Myasthenia Gravis (EAMG). 
However its relevance in humans had never been tested. We investigated whether this peptide would 
be significant in human patients with MG. Our results showed that the anti-MIR peptide antibodies 
titres in serum from seropositive patients with MG were no different from those found in seronegative 
patients or healthy controls, which suggests that the MIR peptide might not be the main immunogenic 
region targeted by autoantibodies in human MG.  
We then decided to confirm these results using a different method and used flow cytometry to 
determine whether these patients had CD20 B-Lymphocytes that would express the anti-MIR 
membrane immunoglobulins. This second set of experiments reinforced the results previously 
obtained in which the MIR peptide had not been recognized by the autoantibodies as a main target in 
patients with Myasthenia Gravis, contrarily to what was reported in animal models of this disease. We 
find these results very important as they highlight the limitations that the use of these models might 
have when attempting to study the mechanisms of human MG. 
Consequently, it became essential to identify other antigenic regions in the nicotinic acetylcholine 
receptor that could be recognized by the autoantibodies produced in these patients. The alpha1 
subunit of the AchR is its most functionally important subunit, and therefore a potential prime target 
for the immune system that would explain the strong relation between antibody presence and 
receptor dysfunction. Part of this work was directed into synthesising the extracellular domain of this 
subunit as a first attempt to narrow down the antigen site within the receptor.  
The CHRNA1 protein purification was a major time consuming setback in this project and despite our 
continuous attempts it was not possible to purify it.  
However, with this work it was possible to confirm our hypothesis that the alpha1 subunit, being the 
receptor’s subunit which is more biologically active, is an important target for antibody binding as 
≈50% of the autoantibodies from patients with Myasthenia Gravis recognized the CHRNA1 cloned 
protein. Interestingly, these results suggest that other antigenic regions in the nicotinic AchR besides 
the alpha1 subunit should be considered.  
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During this project, we also produced a tool with the aim of identifying the autoantibody-producing B-
cells in patients with MG: a fusion protein constituted by the extracellular domain of the alpha1 
subunit of the AchR (CHRNA1), and the Fc region of an IgG immunoglobulin. Even though most of this 
task has been completed, time limitations did not allow the complete purification of this fusion 
protein. 
Combined together, the results presented here, although preliminary, are very promising in 
redirecting the search for other antigenic targets in the AchR.  
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6. Conclusions  
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The work presented in this thesis is an important step towards determining the specific antigenic 
targets of autoantibodies that bind to the acetylcholine receptor in patients with MG. 
We were able to create tools that enable the screening of the serum of patients with MG for the 
presence of more specific autoantibodies that recognize either the MIR peptide or the alpha1 subunit 
of the AchR, and that may allow the identification of the autoantibody-producing B-cells in these 
patients. 
It is now possible to infer that the MIR peptide described to be the main immunogenic region in 
antibody targeting in animal models of the disease (EAMG), may not be the same as in humans. 
Moreover, we showed that the serum from seropositive patients with MG had antibodies directed 
towards the CHRNA1 suggesting that this subunit is an important target of antibody binding in MG. 
Adding to the fact that these results may lead to the creation of a more specific tool for the diagnosis 
and clinical monitoring of the disease, the identification of CD20 cells as the lymphocytes responsible 
for the production of the pathogenic antibodies would allow the possibility of using specific anti-CD20 
drugs (such as rituximab) in the overall treatment of the disease or in specific subsets of patients, 
defined by the type of antibodies they would carry. 
Furthermore, the finding of the antibody’s specific target may result in the development of a fusion 
protein capable of binding to anti-AchR autoantibodies and subsequently blocking their linkage to the 
AchR, creating in this fashion a new class of drugs for the treatment of this disease. 
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7. Future work 
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The work presented here is still a preliminary work and further studies are needed. The localization, 
structure and antigenic properties of the binding site of the antibodies to the acetylcholine receptor, 
and the full comprehension and characterization of both B lymphocytes and immunoglobulins 
involved in the pathogenicity of this disease are crucial to the development of new biomarkers and 
new drugsfor Myasthenia Gravis.  
Due to unexpected obstacles during this project’s development it was not possible to purify the 
proteins produced by cloning, nevertheless in future work we intend to successfully perform this task 
and create a vast panel of peptides to test antibody binding and determine the specific area that is 
targeted by the autoantibodies. Furthermore we aim to determine whether CD20+ B lymphocytes are 
responsible for the production of these pathogenic antibodies.  
The use of the tolls developed in (or following) this project may be decisive in the implementation of 
new diagnostic and therapeutic strategies leading to a personalized and more efficient medical care of 
these patients.  
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Appendix 1 – ELISA method 
 
 
 
 
 
 
 
 
 
 
 
Half-coated 
 
1,5 μg/mL of synthetic MIR 
peptide 
Half-uncoated 
 5 μg/mL of CHRNA1 
protein 
Incubate overnight at 4ºC 
Blocking buffer 
Incubate 1h at 37ºC 
Washing step 
Add serum samples 
Washing step 
Add Conjugated antibody 
Washing step 
Add specific substrate 
Read optical density at 495nm with 
reference to 605nm 
 
Incubate 1h at 37ºC 
Incubate 1h at 37ºC 
Incubate 1h at 37ºC 
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Appendix 2 – pT7 vector  
 
 
 
 
Histidine-TAG 
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Appendix 3 – synthetic gene CHRNA1  
 
 
 
 
 
 
 
 
 
 67 
 
Appendix 4 – pFuse-hIgG1e1-Fc2 vector 
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